Novartis to Evaluate Quanterix Platform for Dx Use | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Quanterix said today it has entered an agreement with Novartis to evaluate its Single Molecule Array, or SiMoA, platform for diagnostic use.

The platform will be evaluated at Quanterix, based in Cambridge, Mass., and will focus on an undisclosed neuron-specific protein target. Financial and other terms of the deal were also undisclosed.

The SiMoA platform is used for the development and commercialization of blood tests that measure protein levels in blood.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: certain genes repressed during memory formation, analysis of genomes from single neurons, and more.

NASA plans to test whether DNA sequencing studies can be conducted in microgravity.

Congress passes a continuing resolution to keep the US federal government funded through mid-December.

The Human Genome Project was launched 25 years ago, and at Nature, Francis Collins, James Watson, and Eric Green look back at the lessons learned.